Reports Q2 revenue $179M, consensus $174.03M. Cash, cash equivalents, and marketable securities were $1,989.2M as of June 30, 2025 vs. $1,139.7M as of December 31, 2024. “We had another strong quarter highlighted by the first approvals of Sephience for the treatment of children and adults with PKU,” said CEO Matthew Klein. “We have initiated the global launch and expect Sephience to be the foundational product for PTC’s future growth and path to profitability.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics: Strategic Shift and Robust Financials Drive Buy Rating with $68 Target by 2025
- PTC Therapeutics price target raised to $68 from $67 at JPMorgan
- PTC Therapeutics (PTCT) Q2 Earnings Cheat Sheet
- PTC Therapeutics’ Future at Risk: Navigating Operational and Financial Challenges
- PTC Therapeutics price target raised to $84 from $68 at BofA